387 related articles for article (PubMed ID: 25929843)
1. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
3. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
[TBL] [Abstract][Full Text] [Related]
5. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Ebrahimi-Fakhari D; Franz DN
Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
[TBL] [Abstract][Full Text] [Related]
7. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
9. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
Jiang T; Du J; Raynald ; Wang J; Li C
World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
[TBL] [Abstract][Full Text] [Related]
10. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
Jóźwiak S; Nabbout R; Curatolo P;
Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
[TBL] [Abstract][Full Text] [Related]
11. Subependymal giant-cell astrocytoma: A surgical review in the modern era of mTOR inhibitors.
Danassegarane G; Tinois J; Sahler Y; Aouaissia S; Riffaud L
Neurochirurgie; 2022 Dec; 68(6):627-636. PubMed ID: 35907444
[TBL] [Abstract][Full Text] [Related]
12. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
[TBL] [Abstract][Full Text] [Related]
13. Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.
Katz JS; Frankel H; Ma T; Zagzag D; Liechty B; Zeev BB; Tzadok M; Devinsky O; Weiner HL; Roth J
Childs Nerv Syst; 2017 Apr; 33(4):601-607. PubMed ID: 28074282
[TBL] [Abstract][Full Text] [Related]
14. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
Major P
Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
[TBL] [Abstract][Full Text] [Related]
15. Isolated subependymal giant cell astrocytoma (SEGA) in the absence of clinical tuberous sclerosis: two case reports and literature review.
Cobourn KD; Chesney KM; Mueller K; Fayed I; Tsering D; Keating RF
Childs Nerv Syst; 2024 Jan; 40(1):73-78. PubMed ID: 37658938
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
[TBL] [Abstract][Full Text] [Related]
17. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
Appalla D; Depalma A; Calderwood S
Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
[TBL] [Abstract][Full Text] [Related]
18. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus.
Zipori AB; Tehrani NN; Ali A
J AAPOS; 2018 Feb; 22(1):76-79. PubMed ID: 29277498
[TBL] [Abstract][Full Text] [Related]
19. Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex.
Tsai JD; Wei CC; Tsao TF; Hsiao YP; Tsai HJ; Yang SH; Tsai ML; Sheu JN
Childs Nerv Syst; 2016 Jan; 32(1):89-95. PubMed ID: 26552385
[TBL] [Abstract][Full Text] [Related]
20. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]